Trending logo Trending

Play Pause Stop
science

Reviving ghost alleles: Genetically admixed coyotes along the American Gulf Coast are critical for saving the endangered red wolf

Science Advances
10.1126/sciadv.abn7731
Article
Abstract

The last known red wolves were captured in southwestern Louisiana and eastern Texas in 1980 to establish a captive breeding population. Before their extirpation, gene flow with coyotes resulted in the persistence of endangered red wolf genetic variation in local coyote populations. We assessed genomic ancestry and morphology of coyotes in southwestern Louisiana. We detected that 38 to 62% of the coyote genomes contained red wolf ancestry acquired in the past 30 years and have an admixture profile similar to that of the canids captured before the extirpation of red wolves. We further documented a positive correlation between ancestry and weight. Our findings highlight the importance of hybrids and admixed genomes as a reservoir of endangered species ancestry for innovative conservation efforts. Together, this work presents an unprecedented system that conservation can leverage to enrich the recovery program of an endangered species.

Intermittent fasting linked to better gut and liver function in mice

New Scientist: News
Jun 29, 2022
Article
Abstract

Limiting meals to an 8 hour window each day regulates the circadian rhythm of multiple organs in mice, potentially staving off chronic disease

The C.E.O. Silence on the Jan. 6 Hearings

Andrew Ross Sorkin, Vivian Giang, Stephen Gandel, Lauren Hirsch, Ephrat Livni, Jenny Gross, David F. Gallagher

The New York Times: Business
Jun 29, 2022
Article
Abstract

Some business leaders say they fear retaliation for speaking out. Others point to ‘outrage fatigue.’

Volatile versus propofol general anesthesia and long-term survival after breast cancer surgery: a national registry retrospective cohort study.

Mats Enlund, Anders Berglund, Anna Enlund, Leif Bergkvist

Anesthesiology
Jun 28, 2022
10.1097/aln.0000000000004309
Article
Abstract

Several retrospective studies using administrative or single center data have failed to show any difference between general anesthesia using propofol versus inhaled volatiles on long-term survival after breast cancer surgery. Although randomized controlled trials are ongoing, validated data from national clinical registries may advance the reliability of existing knowledge. Data on breast cancer surgery performed under general anesthesia between 2013 and 2019 from The Swedish PeriOperative Register and The National Quality Register for Breast Cancer were record-linked. Overall survival was compared between patients receiving propofol or inhaled volatile for anesthesia maintenance. Of 18,674 subjects, 13,873 patients (74.3%) received propofol and 4,801 (25.7%) received an inhaled volatile for general anesthesia maintenance. The two cohorts differed in most respects. Patients receiving inhaled volatile were older (67 years vs 65 years), sicker (888 [19.0%] ASA status 3-5 versus 1,742 [12.8%]), and the breast cancer to be more advanced. Median follow-up was 33 months (IQR, 19 to 48). In the full, unmatched cohort, there was a statistically significantly higher overall survival among patients receiving propofol (13,489/ 13,873 (97.2%)) versus inhaled volatile (4,039/4,801 (84.1%)) hazard ratio = 0.80 (95% CI 0.70-0.90, P < 0.001). Following 1:1 propensity score matching (4,658 matched pairs) there was no statistically significant difference in overall survival, (propofol 4,284/4,658 (92.0%) versus inhaled volatile 4,288/4,658 (92.1%) hazard ratio = 0.98 (95% CI 0.85-1.13, P = 0.756)). Among patients undergoing breast cancer surgery under general anesthesia, no association was observed between the choice of propofol or an inhaled volatile maintenance and overall survival.

Awake extracorporeal life support and physiotherapy in adult patients: A systematic review of the literature

Marta Cucchi, Silvia Mariani, Maria E De Piero, Justine M Ravaux, Michal J Kawczynski, Michele Di Mauro, Emma Shkurka, Aparna Hoskote, Roberto Lorusso

Perfusion
10.1177/02676591221096078
Article
Abstract

Perfusion, Ahead of Print.
Objective The Awake Extracorporeal Life Support (ECLS) practice combined with physiotherapy is increasing. However, available evidence for this approach is limited, with unclear indications on timing, management, and protocols. This review summarizes available literature regarding Awake ECLS and physiotherapy application rates, practices, and outcomes in adults, providing indications for future investigations.
Method Four databases were screened from inception to February 2021, for studies reporting adult Awake ECLS with/without physiotherapy. Primary outcome was hospital discharge survival, followed by Extracorporeal Membrane Oxygenation (ECMO) duration, extubation, Intensive Care Unit stay.
Result Twenty nine observational studies and one randomized study were selected, including 1,157 patients (males n = 611/691, 88.4%) undergoing Awake ECLS. Support type was reported in 1,089 patients: Veno Arterial ECMO (V A = 39.6%), Veno Venous ECMO (V V = 56.8%), other ECLS (3.6%). Exclusive upper body cannulation and femoral cannulation were applied in 31% versus 69% reported cases (n = 931). Extubation was successful in 63.5% (n = 522/822) patients during ECLS. Physiotherapy details were given for 676 patients: exercises confined in bed for 47.9% (n = 324) patients, mobilization until standing in 9.3% (n = 63) cases, ambulation performed in 42.7% (n = 289) patients. Femoral cannulation, extubation and V A ECMO were mostly correlated to complications. Hospital discharge survival observed in 70.8% (n = 789/1114).
Conclusion Awake ECLS strategy associated with physiotherapy is performed regardless of cannulation approach. Ambulation, as main objective, is achieved in almost half the population examined. Prospective studies are needed to evaluate safety and efficacy of physiotherapy during Awake ECLS, and suitable patient selection. Guidelines are required to identify appropriate assessment/evaluation tools for Awake ECLS patients monitoring.

cardiology

Rehabilitation effects of circuit resistance training in coronary heart disease patients: A systematic review and meta-analysis.

Chunchun Wu, Rongsheng Bu, Yaoguo Wang, Chaoxiang Xu, Youfang Chen, Lishuang Che, Shengnan Wang

Clinical cardiology
Jun 27, 2022
10.1002/clc.23855
Free icon
Article PDF
Abstract

The rehabilitation effect of circuit resistance training in coronary heart disease (CHD) patients remains unclear. We perform this review to examine the rehabilitation effect of circuit resistance training in CHD patients and to provide a basis for the formulation of reasonable individual exercise prescriptions for CHD patients. Randomized controlled trials (RCTs) were searched on PubMed, Web of Science, The Cochrane Library, Embase, Clinical Trials, and CNKI. About 1232 studies were identified. Nine RCTs were finally used for the present meta-analysis to determine the rehabilitation effect of circuit resistance training in CHD patients, compared to aerobic training. Individuals enrolled for the studies were at a mean age of 60.5 years old and were all CHD patients. Following the PRISMA guidelines, we extracted basic information about the study and patient characteristics, as well as measurements (e.g., the peak oxygen uptake, the body mass index [BMI], the body fat percentage, the systolic blood pressure, the total cholesterol, and triglycerides). Subsequently, this meta-analysis determined the overall effect by using standardized mean difference (SMD) and 95% confidence interval (CI). Compared with aerobic training, circuit resistance training significantly decrease the BMI and the body fat percentage. As suggested from the present meta-analysis of RCTs, circuit resistance training is effective in improving the BMI and the body fat percentage in CHD patients and may help delay the progression of CHD. CRT has the advantage of lower load in most cases with a similar effect.

oncology

Cancers, Vol. 14, Pages 3166: Specialist versus Primary Care Prostate Cancer Follow Up: A Process Evaluation of a Randomized Controlled Trial

Barbara M. Wollersheim, Kristel M. van Asselt, Floris J. Pos, Emine Akdemir, Shifra Crouse, Henk G. van der Poel, Neil K. Aaronson, Lonneke V. van de Poll-Franse, Annelies H. Boekhout

Cancers
Jun 28, 2022
10.3390/cancers14133166
Article
Abstract

Cancers, Vol. 14, Pages 3166: Specialist versus Primary Care Prostate Cancer Follow Up: A Process Evaluation of a Randomized Controlled Trial Cancers doi: 10.3390/cancers14133166 Authors: Barbara M. Wollersheim Kristel M. van Asselt Floris J. Pos Emine Akdemir Shifra Crouse Henk G. van der Poel Neil K. Aaronson Lonneke V. van de Poll Franse Annelies H. Boekhout
Background : A randomized controlled trial (RCT) is currently comparing the effectiveness of specialist versus primary care based prostate cancer follow up. This process evaluation assesses the reach and identified constructs for the implementation of primary care based follow up.
Method : A mixed methods approach is used to assess the reach and the implementation through the Consolidated Framework for Implementation Research. We use quantitative data to evaluate the reach of the RCT and qualitative data (interviews) to indicate the perspectives of patients (n = 15), general practitioners (GPs) (n = 10), and specialists (n = 8). Thematic analysis is used to analyze the interview transcripts.
Result : In total, we reached 402 (67%) patients from 12 hospitals and randomized them to specialist (n = 201) or to primary care based (n = 201) follow up. From the interviews, we identify several advantages of primary care versus specialist based follow up: it is closer to home, more accessible, and the relationship is more personal. Nevertheless, participants also identified challenges: guidelines should be implemented, communication and collaboration between primary and secondary care should be improved, quality indicators should be collected, and GPs should be compensated.
Conclusion : Within an RCT context, 402 (67%) patients and their GPs were willing to receive/provide primary care based follow up. If the RCT shows that primary care is equally as effective as specialist based follow up, the challenges identified in this study need to be addressed to enable a smooth transition of prostate cancer follow up to primary care.

Healthcare, Vol. 10, Pages 1212: The Effect of Type of Delivery on Female Postpartum Sexual Functioning: A Systematic Review

Effrosyni Nikolaidou, Evangelia Antoniou, Angeliki Sarella, Maria Iliadou, Eirini Orovou, Maria Dagla

Healthcare
Jun 28, 2022
10.3390/healthcare10071212
Article
Abstract

Healthcare, Vol. 10, Pages 1212: The Effect of Type of Delivery on Female Postpartum Sexual Functioning: A Systematic Review Healthcare doi: 10.3390/healthcare10071212 Authors: Effrosyni Nikolaidou Evangelia Antoniou Angeliki Sarella Maria Iliadou Eirini Orovou Maria Dagla Female sexual function could be considered as multifactorial. Specific physiological structures and hormonal fluctuations postpartum, along with the psychological adjustment of women, could result in altered sexual function. The primary aim of this review was to systematically appraise the existing data on the effect of mode of delivery on female sexual function. This review was designed based on the PRISMA statement guidelines. An extensive literature search was performed in the Pubmed, Scopus, and PsycInfo databases, using prespecified inclusion/exclusion criteria, between the 20 September and 10 October 2021. Studies quality assessment was conducted using the Quality Assessment Tool for Observational Cohort and Cross Sectional Studies of the National Heart, Lung, and Blood Institute. The initial search involved 1592 studies. The last step of the screening procedure yielded 16 studies, including 41,441 subjects with a mean age of 29.9 years. Studies included groups with spontaneous and assisted vaginal and C section delivery modes. No statistically significant difference between groups was found. The type of delivery appears to be irrelevant regarding this relationship. Moderating factors seemed to indirectly influence this relationship. Health professionals should educate expectant mothers and be aware of the possibility that delivery method could affect sexual function.

medicine

JCM, Vol. 11, Pages 3751: Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER AF and PREFER AF Prolongation Registries

Vincenzo Russo, Emilio Attena, Matteo Baroni, Roberta Trotta, Marius Constantin Manu, Paulus Kirchhof, Raffaele De Caterina

Journal of Clinical Medicine
Jun 28, 2022
10.3390/jcm11133751
Article
Abstract

JCM, Vol. 11, Pages 3751: Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER AF and PREFER AF Prolongation Registries Journal of Clinical Medicine doi: 10.3390/jcm11133751 Authors: Vincenzo Russo Emilio Attena Matteo Baroni Roberta Trotta Marius Constantin Manu Paulus Kirchhof Raffaele De Caterina
Background : Elderly patients are at high risk of both ischaemic and bleeding events, and the low body weight is considered a risk factor for major bleeding in atrial fibrillation (AF) patients on anticoagulation therapy. The aim of our study was to compare the safety and effectiveness of non vitamin K antagonist oral anticoagulants (NOACs) versus well controlled vitamin K antagonists (VKA) therapy among AF patients aged >75 years and with a body weight <60 kg in a prospective registry setting.
Method : Data for this study were sourced from the Italian cohorts of PREFER in AF and PREFER in AF PROLONGATION registries. The occurrence of a composite of stroke, transient ischemic attack and systemic embolism (thromboembolic events) was the primary effectiveness endpoint. The occurrence of major bleeding was the primary safety endpoint. All cause hospitalizations and all cause death were the secondary endpoints. The net clinical benefit (NCB) was calculated in order to obtain an integrated assessment of the anti thromboembolic and pro haemorrhagic effects of NOACs vs. VKA.
Result : Overall, 522 patients were included; 225 were on treatment with NOACs and 317 patients with VKA. The NOAC group more frequently featured a higher BMI and a higher prevalence of history of stroke/TIA and insulin requiring diabetes; conversely, heart failure and chronic liver disease were less frequent in the NAOC group. In the unmatched study population, 18 patients (3.6% in the NOAC vs. 3.2% in the VKA group, p = 0.79) experienced thromboembolic events; 19 patients (1.78% in the NOAC vs. 4.73% in the VKA group, p = 0.06) experienced major bleeding events; and 68 patients were hospitalized during the follow up (9.3% vs. 14.8%, p = 0.06). After balancing for potential confounders by using the 1:1 propensity score matching technique, 426 patients (213 on NOAC and 213 on VKA) were selected. We found no significant differences in terms of thromboembolic events (3.76% vs. 4.69%, p = 0.63), major bleeding events (n: 1.88% vs. 4.22%, p = 0.15) and hospitalizations (9.9% vs. 16.9%, p = 0.06) between NOAC vs. VKA matched population. Based on these incidences, we found a positive net clinical benefit (+1.6) of NOACs vs. VKAs.
Conclusions : These real world data suggest the safety and effectiveness of using NOACs in elderly patients with low body weight.

DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugsDUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制

Weiqing Wang, Bue F. Ross Agner, Bin Luo, Lei Liu, Ming Liu, Yongde Peng, Shen Qu, Karolina Amelia Stachlewska, Guixia Wang, Guoyue Yuan, Qiu Zhang, Guang Ning

Journal of Diabetes
Jun 28, 2022
10.1111/1753-0407.13286
Article
Figure
DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugsDUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制
Abstract

Highlights Insulin degludec/liraglutide (IDegLira) has good efficacy and tolerability in Chinese adults with type 2 diabetes not controlled on oral antidiabetic drugs. IDegLira provides the clinical advantages of insulin and glucagon like peptide 1 receptor agonists, improving glycemic control while reducing the main adverse effects of insulin (weight gain) and liraglutide (gastrointestinal events). As IDegLira is given as a once daily single injection, fewer injections are required versus administering the individual components separately.

Background DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs).
Method This phase 3a, treat to target multicenter trial randomized participants (glycated hemoglobin 53.0 85.8 mmol/mol; previous metformin ± another OAD) 2:1:1 to IDegLira (n = 361), degludec (n = 179), or liraglutide (n = 180). Primary endpoint was change in HbA1c after 26 weeks. Secondary endpoints included: HbA1c < 53.0 mmol/mol attainment, weight change, treatment emergent hypoglycemia, end of treatment insulin dose, and safety.
Result At 26 weeks, HbA1c had decreased by a mean 18.12 mmoL/moL (IDegLira), 12.37 mmoL/moL (degludec) (estimated treatment difference −6.50 mmoL/moL; 95% confidence interval −7.96, −5.04; P < .0001), and 11.33 mmoL/moL (liraglutide) (ETD −6.87 mmoL/moL; 95% CI −8.33, −5.41; P < 0.0001), indicating noninferiority for IDegLira vs degludec and superiority vs liraglutide. HbA1c < 53.0 mmoL/moL attainment was 77.0% (IDegLira), 46.4% (degludec), and 48.3% (liraglutide). Mean weight change with IDegLira (0.1 kg) was superior to degludec (1.2 kg) (ETD −1.08 kg; 96% CI −1.55, −0.62; P < 0.0001). Severe or confirmed hypoglycemic event rates were 0.24 (IDegLira) and 0.17 (degludec) episodes/participant year (estimated rate ratio 1.46; 95% CI 0.71, 3.02; P = .3008, not significant). At the end of treatment, the IDegLira insulin dose was lower (24.5 U/d) vs degludec (30.3 U/d) (ETD −5.49 U; 95% CI −7.77, −3.21; P < 0.0001). No unexpected safety issues occurred.
Conclusions IDegLira is efficacious and well tolerated in Chinese adults with T2D not controlled by OADs. 摘要 背景 作为DUAL试验之一的DUAL I China评估了未口服抗糖药物(OADs)控制血糖的中国成人2型糖尿病(T2D)患者应用德谷胰岛素/利拉鲁肽(IDegLira)的有效性/安全性。 方法 这项3a期, 治疗导向的多中心随机对照试验中, 受试者糖化血红蛋白(HbA1c)为53.0 85.8 mmol/mol, 之前治疗为二甲双胍配合或不配合其他口服抗糖药物。按2:1:1的比例分别给予IDegLira(n=361), 德谷胰岛素(n=179)或利拉鲁肽(n=180)。主要终点是26周后HbA1c的变化。次要终点包括:HbA1c<53.0 mmol/mol, 体重变化, 治疗后出现的低血糖, 治疗结束时的胰岛素剂量, 以及安全性。 结果 治疗26周时, 糖化血红蛋白平均下降18.12mmol/mol(IDegLira), 12.37mmol/mol(德谷胰岛素)(治疗前后差值估计(ETD)为 6.50 mmoL/m ol, 95%可信区间−7.96, −5.04, P<0.0001)和11.33 mmoL/mol(利拉鲁肽)(ETD−6.87 mmoL/mol, 95%置信区间−8.33, −5.41, P<0.0001), 表明IDegLira相对于德谷胰岛素的非劣效性, 以及相对于利拉鲁肽的优越性。糖化血红蛋白(HbA1c)的达标率为77.0%(IDegLira), 46.4%(德谷胰岛素)和48.3%(利拉鲁肽)。平均体重变化:IDegLira组(0.1 kg)优于德谷胰岛素组(1.2 kg), ETD为 1.08 kg(95%CI−1.5 5, −0.62), P<0.001。严重或确认的低血糖事件发生率分别为0.24(IDegLira)和0.17(德谷胰岛素)次/参与者 年, 估计比率为1.46(95%CI:0.71, 3.02), P=.3008, 无显著意义。治疗结束时, IDegLira胰岛素剂量(24.5U/天)低于德谷胰岛素(30.3U/天), ETD为 5.49U, P<0.0001。没有发生意外安全事件。 结论 IDegLira治疗非OADs控制的中国成人T2D是有效的且耐受性良好。

Manipulative and body based methods in chronic kidney disease patients: A systematic review of randomized controlled trials

Complementary Therapies in Clinical Practice
Jun 28, 2022
Article
Abstract

Complementary Therapies in Clinical Practice, Volume 48, 2022 Aug, Article 101593 | Chu, Shu Wen Felicia; Ng, Wei Jie; Yeam, Cheng Teng;...
Backgroundand purpose: Among chronic kidney disease (CKD) patients, manipulative and body based methods (MBM) have demonstrated efficacy in improving symptoms such as fatigue. This review aims to summarize the efficacy and safety of MBM am...

Antioxidants, Vol. 11, Pages 1287: Oxidative Stress and Fetal Growth Restriction Set Up Earlier in Undernourished Sheep Twin Pregnancies: Prevention with Antioxidant and Nutritional Supplementation

Víctor H. Parraguez, Francisco Sales, Oscar Peralta, Monica De los Reyes, Antonio Gonzalez-Bulnes

Antioxidants
Jun 28, 2022
10.3390/antiox11071287
Article
Abstract

Antioxidants, Vol. 11, Pages 1287: Oxidative Stress and Fetal Growth Restriction Set Up Earlier in Undernourished Sheep Twin Pregnancies: Prevention with Antioxidant and Nutritional Supplementation Antioxidants doi: 10.3390/antiox11071287 Authors: Víctor H. Parraguez Francisco Sales Oscar Peralta Monica De los Reyes Antonio Gonzalez Bulnes Hypoxemia and oxidative stress, resulting in intrauterine growth restriction (IUGR) in undernourished twin sheep pregnancies, has been described in near term studies. Our aim was to evaluate if the counteractive effects of maternal nutritional or antioxidant supplementation on the fetal redox status were evident before the accelerated fetal growth phase. Forty twin bearing ewes grazing on natural Patagonian prairie were randomly assigned to four groups (n = 10 each; P: control ewes consuming mainly natural pasture; P+A: pasture plus antioxidants; P+C: pasture plus concentrate; P+A+C: pasture plus antioxidants and concentrate). Daily herbal antioxidants were supplemented in a feedstuff concentrate as a premix from day 35 until day 100 of gestation, when fetal venous cord blood samples and biometric measurements were obtained via cesarean section. The fetuses from group P were clearly hypoxemic. An analysis of variance showed that maternal antioxidant supplementation showed a trend of increased PO2, SatHb, and Ht, effects not observed in P+C fetuses. Antioxidants decreased the fetal MDA concentration (p < 0.05). Fetal TAC was increased by the antioxidants and concentrate (p < 0.05). Antioxidant supplementation showed a trend to increase fetal body weight but not biometry. The results suggest that negative effects of oxidative stress occur earlier than the overt growth arrest, and the maternal administration of antioxidants may constitute a good nutritional strategy for the early prevention of IUGR.

Correction: Does the combination of resistance training and a nutritional intervention have a synergic effect on muscle mass, strength, and physical function in older adults? A systematic review and meta analysis

MoonKi Choi, Hayeon Kim, Juyeon Bae

BMC Geriatrics
Jun 28, 2022
10.1186/s12877-022-03110-7
Article
oncology

Current Oncology, Vol. 29, Pages 4578 4586: Achieving Consensus for Management of Hormone Sensitive, Low Volume Metastatic Prostate Cancer in Italy

Elena Verzoni, Giovanni Pappagallo, Filippo Alongi, Stefano Arcangeli, Giulio Francolini, Daniele Galanti, Luca Galli, Marco Maruzzo, Sabrina Rossetti, Giambattista Siepe, Luca Triggiani, Paolo Andrea Zucali, Rolando Maria D’Angelillo

Current Oncology
Jun 28, 2022
10.3390/curroncol29070362
Article
Abstract

(This summary has been generated by AI. Generate your own summaries: https://www.welcome.alviss.ai/alboard/#/editorial)
Introduction : achieving consensus for management of hormone sensitive, low volume metastatic prostate cancer in italy current oncology doi: 10.3390/curroncol29070362 authors : elena verzoni giovanni pappagallo filippo alongi stefano arcangeli giulio francolini daniele galanti luca galli marco maruzzo sabrina rossetti giambattista siepe luca triggiani paolo andrea zucali rolando maria d'angelillo metastatic hormone sensitive prostate cancer is usually categorized as high or low volume disease. Although some definitions have been reported, the concept of oligometastatic disease is not so clearly defined, giving rise to further variability in the choice of treatment, mainly between systemic agents and radiotherapy, especially in the era of metastasis directed therapy. Discussion: this is relevant because low and high volume metastases disease are associated with different outcomes, and thus management of the two forms should differ.
Conclusion : with regard to clinical definitions of mHSPC, it was held that oligometastic and low - volume disease refer to different concepts and should not be used interchangeably ; regarding therapy of de novo low volume of metastatic disease, androgen deprivation therapy alone can be considered undertreatment, and all patients should be evaluated for systemic treatment combinations ; local therapy , regardless of the intensity of systemic therapy, and metastasis - directed therapy can be proposed in selected cases.

Transplantology, Vol. 3, Pages 208 218: Safety of Non Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

Mikołaj Młyński, Mikołaj Sajek, Zbigniew Heleniak, Alicja Dębska-Ślizień

Transplantology
Jun 28, 2022
10.3390/transplantology3030022
Article
Abstract

Transplantology, Vol. 3, Pages 208 218: Safety of Non Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients Transplantology doi: 10.3390/transplantology3030022 Authors: Mikołaj Młyński Mikołaj Sajek Zbigniew Heleniak Alicja Dębska Ślizień The use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug to drug interactions and anticoagulation related adverse events. This article aims to assess the current data on the safety of direct acting oral anticoagulant based therapy in the population of kidney transplant recipients and patients with impaired renal function. The most important factors affecting the safety of treatment are the incidence of bleeding events, thromboembolic events, deaths and drug to drug interactions. The available data were compared to the findings on warfarin based anticoagulation. Findings on the use of novel oral anticoagulants in kidney transplant recipients are limited yet promising in terms of safety and efficacy of use. However, current recommendations state that the co administration of non vitamin K antagonist oral anticoagulants with several immunosuppressive agents is contraindicated.

Agriculture, Vol. 12, Pages 939: Growth Performance, Meat Quality, and Fecal Microbial Population in Limousin Bulls Supplemented with Hydrolyzable Tannins

Andrej Mergeduš, Marjan Janžekovič, Dejan Škorjanc, Tadeja Kraner Šumenjak, Maksimiljan Brus

Agriculture
Jun 28, 2022
10.3390/agriculture12070939
Article
Abstract

Agriculture, Vol. 12, Pages 939: Growth Performance, Meat Quality, and Fecal Microbial Population in Limousin Bulls Supplemented with Hydrolyzable Tannins Agriculture doi: 10.3390/agriculture12070939 Authors: Andrej Mergeduš Marjan Janžekovič Dejan Škorjanc Tadeja Kraner Šumenjak Maksimiljan Brus The objective of this study was to investigate the effects of supplementation of hydrolyzable tannins (HT) from sweet chestnut wood extract (Castanea sativa Mill.) to the diet of Limousin bulls on growth rate, carcass and meat quality traits, and fecal Clostridia strain levels in a 7 month feeding trial. Thirty two bulls were randomly assigned to four treatment groups (CON (without addition of HT); TAN 1 (1 g HT kg-1 DM); TAN 2 (1.5 g HT kg-1 DM); and TAN 3 (1.5 g HT kg-1 DM with a nominally lower dose of concentrate). Compared with the CON group, supplementation with HT significantly (p < 0.050) increased bull growth rate during 4-7 months, whereas carcass and meat quality traits were unaffected during the last three months of fattening. Supplementation of HT significantly reduced meat drip loss (p = 0.000) compared with the CON group. No effects were observed on the total number of fecal Clostridia strains; however, the concentration of Clostridiumperfringens was significantly lower (p = 0.004) in TAN 1 than that in the CON group. The results obtained in fattening bulls indicate that the addition of HT is justified in practice to improve growth performance and feed efficiency without adverse effects on the carcass and meat quality.

Sustainability, Vol. 14, Pages 7892: Sustainable Supply Chain Management: A Comprehensive Systematic Review of Industrial Practices

Ehsan Shekarian, Behrang Ijadi, Amirreza Zare, Jukka Majava

Sustainability
Jun 28, 2022
10.3390/su14137892
Article
Abstract

Sustainability, Vol. 14, Pages 7892: Sustainable Supply Chain Management: A Comprehensive Systematic Review of Industrial Practices Sustainability doi: 10.3390/su14137892 Authors: Ehsan Shekarian Behrang Ijadi Amirreza Zare Jukka Majava Sustainable business practices are those that allow companies to increase their profit while still considering the triple bottom line of sustainability, which involves economic, environmental, and social aspects. There are a lot of studies exploring various aspects of supply chain practices. However, there remains a gap for the proposal of a complete framework concerning various industries. This research fills this gap by studying existing empirical and review studies. Based on a content analysis of 86 studies, 789 practices are derived and categorized, leading to a comprehensive classification of sustainable practices in supply chains. Moreover, the employed methods to analyze the data are investigated. The practices are cross checked versus the studied industries showing the current sustainable industries. The details of the studied papers are presented in a comprehensive table. The sustainable framework showing the industrial solutions toward sustainable supply chains is divided into 38 minor practices classified into 11 main categories. This paper provides a novel interpretation of the sustainable solutions addressed by different industries and presents a new and updated classification of the literature identifying future directions. This offers many advantages for practitioners and researchers to transform a supply chain into an improved version in the bigger picture.

medicine

JCM, Vol. 11, Pages 3752: Prevalence and Risk of Infection in Patients with Diabetes following Primary Total Knee Arthroplasty: A Global Systematic Review and Meta Analysis of 120,754 Knees

Ahmad, Ab Rahman, Islam

Journal of Clinical Medicine
Jun 28, 2022
10.3390/jcm11133752
Article
Abstract

(This summary has been generated by AI. Generate your own summaries: https://www.welcome.alviss.ai/alboard/#/editorial)
Background : diabetes mellitus is a known risk factor for infection following total joint arthroplasty. This study looked at the prevalence and risk of infection in diabetic and non diabetic patients who had primary total kaposi's sarcoma ( TKA).
Method : PUBMED, Scopus, Google Scholar, web of science, and science direct electronic databases were searched for studies published up to 21 april 2022. results: a total of 119,244 participants from 18 studies, with a total of 120,754 knees, were included in the meta analysis. Infection was more common in diabetic patients ( 1.9%, 95% CI 1.2 - 2.2% ) than in non diabetic ( 0.7%, 1.0 - 1.5% ) patients. To compare the risk of infections between diabetic and nondiabetic subjects, a pooled prevalence, and a risk ratio with 95% confidence intervals were used.
Conclusion : we discovered that the risks of infection among diabetic patients were 1.84 times significantly higher than those in non - diabetic patients.

Narrow diameter implants to replace congenital missing maxillary lateral incisors: a 1‐year prospective, controlled, clinical study

Andrea Roccuzzo, Jean‐Claude Imber, Jakob Lempert, Mandana Hosseini, Simon Storgård Jensen

Clinical Oral Implants Research
Jun 28, 2022
10.1111/clr.13966
Article
Abstract


Objective To report the clinical, radiographic, aesthetic and patient reported outcomes after placement of a newly developed Narrow Diameter Implant (NDI) in patients with congenitally Missing Lateral Incisors (MLIs). Materials and methods Patients with MLIs with a mesio distal distance between the canine and the central incisor of 5.9 6.3mm received a dental implant with a diameter of 2.9mm (Test), while a diameter of 3.3mm (Control) was used when the distance was 6.4 7.1mm. After healing, a cement retained bi layered zirconia crown was fabricated. At the 1 year follow up (T2), implant survival rate, marginal Crestal Bone Level (CBL) changes, biological and technical complications were registered. The aesthetic outcome was assessed by using the Copenhagen Index Score, and the patient reported outcomes were recorded using the OHIP 49 questionnaire.
Result One hundred patients rehabilitated with 100 dental implants Ø2.9mm (n = 50) or Ø3.3mm (n = 50) were included. One Ø3.3mm implant was lost and 7 patients dropped out of the study, yielding an implant survival rate of 99% (p = 1.000). At T2 a CBL of 0.19 ± 0.25 mm (Test) and 0.25 ± 0.31 mm (Control) was detected, with no statistically significant difference between the groups (p = 0.342). Good to excellent aesthetic scores (id est 1 2) were recorded in most of cases. Technical complications (id est loss of retention, abutment fracture, chipping of veneering ceramic) occurred once in three patients with no statistically significant difference between the groups (p > 0.05). OHIP scores did not differ significantly at follow ups between groups (p = 0.110).
Conclusion The use of Ø2.9mm diameter implants represents as reliable a treatment option as Ø3.3mm implants, in terms of CBL changes, biological and technical complications. Favorable aesthetics and patient reported outcomes were recorded for both groups.

medicine

Lim, Teoh, Yaow, Lin, Masuda, Han, Yeo, Ng

Journal of Clinical Medicine
Jun 28, 2022
10.3390/jcm11133756
Article
Abstract

(This summary has been generated by AI. Generate your own summaries: https://www.welcome.alviss.ai/alboard/#/editorial)
Background : although megestrol acetate is often used off label to stimulate appetite and improve anorexia/cachexia in patients with advanced cancers, the benefits are controversial. The present meta analysis aimed to better elucidate the clinical benefits of MA in cancer patients.
Method : a systematic search of PUBMED, EMBASE, ovid MEDLINE, clinicaltrials dot gov, and Google Scholar databases found 23 clinical trials examining the use of MA as a treatment for cancer related anorexia.
Result : the studies were divided into high dose treatment and low dose treatment. The overall pooled mean change in weight among cancer patients treated with MA, regardless of dosage was 0.75 kg ( 95% CI = -1.64 to 3.15, &tau;2 = 9.35, i2 = 96%). A total of eight studies provided sufficient data on weight change for meta analysis.
Conclusions : on balance, MA did not appear to be effective in providing the symptomatic improvement of anorexyia in advanced cancer patients.